National MS Society: FDA Approves Generic Form of Tecfidera for Relapsing MS
September 03, 2020
September 03, 2020
NEW YORK, Sept. 3 -- The National Multiple Sclerosis Society issued the following news:
The U.S. Food and Drug Administration has approved the first generic version of the oral therapy Tecfidera(R) (dimethyl fumarate, Biogen) for the treatment of relapsing forms of MS.
* Relapsing forms of MS include clinically isolated syndrome (an initial neurological episode), relapsing-remitting MS, and active secondary progressive MS. People with active secondary progressive MS hav . . .
The U.S. Food and Drug Administration has approved the first generic version of the oral therapy Tecfidera(R) (dimethyl fumarate, Biogen) for the treatment of relapsing forms of MS.
* Relapsing forms of MS include clinically isolated syndrome (an initial neurological episode), relapsing-remitting MS, and active secondary progressive MS. People with active secondary progressive MS hav . . .